153 related articles for article (PubMed ID: 37904342)
1. Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom.
Minson A; Hamad N; Di Ciaccio P; Talaulikar D; Ku M; Ratnasingam S; Cheah C; Yannakou CK; Bishton M; Ng ZY; Agrawal S; McQuillan A; Johnston A; Choong E; Wong K; McQuillan J; Beekman A; Hawkes E; Dickinson M
Br J Haematol; 2024 Feb; 204(2):548-554. PubMed ID: 37904342
[TBL] [Abstract][Full Text] [Related]
2. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
[TBL] [Abstract][Full Text] [Related]
3. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
[TBL] [Abstract][Full Text] [Related]
4. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
[TBL] [Abstract][Full Text] [Related]
5. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
Romancik JT; Gerber DG; Zhuang T; Cohen JB
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
7. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
8. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapies in mantle cell lymphoma.
Hanel W; Epperla N
J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
12. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients.
McCulloch R; Lewis D; Crosbie N; Eyre TA; Bolam S; Arasaretnam A; Creasey T; Goradia H; McMillan A; Dawi S; Harrison S; Miles O; Robinson A; Dutton D; Wilson MR; McKay P; Follows G; Phillips N; Patmore R; Lambert J; Bishton M; Osborne W; Johnston R; Kirkwood AA; Rule S
Br J Haematol; 2021 Apr; 193(2):290-298. PubMed ID: 33620106
[TBL] [Abstract][Full Text] [Related]
14. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.
Jiang VC; Hao D; Jain P; Li Y; Cai Q; Yao Y; Nie L; Liu Y; Jin J; Wang W; Lee HH; Che Y; Dai E; Han G; Wang R; Rai K; Futreal A; Flowers C; Wang L; Wang M
Mol Cancer; 2022 Sep; 21(1):185. PubMed ID: 36163179
[TBL] [Abstract][Full Text] [Related]
15. Cellular Therapies for Mantle Cell Lymphoma.
Yassine F; Sandoval-Sus J; Ayala E; Chavez J; Hamadani M; Kharfan-Dabaja MA
Transplant Cell Ther; 2021 May; 27(5):363-370. PubMed ID: 33965173
[TBL] [Abstract][Full Text] [Related]
16. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.
Dreyling M; Aurer I; Cortelazzo S; Hermine O; Hess G; Jerkeman M; Le Gouill S; Ribrag V; Trněný M; Visco C; Walewski J; Zaja F; Zinzani PL
Leuk Lymphoma; 2018 Aug; 59(8):1814-1828. PubMed ID: 29172868
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis.
Yang P; Cai QQ; Zhang W; Liu SZ; Liu H; Sun XH; Dong YJ; Xiao XB; Wang JW; Li ZL; Huang WR; Li LH; Bao HZ; Yang W; Wang YL; Wang SY; He J; Li XL; Liu AC; Jing HM
Cancer Med; 2023 Jun; 12(12):13204-13216. PubMed ID: 37148540
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
Puvvada SD; Guillen-Rodriguez J; Kumar A; Inclán L; Heard K; Rivera XI; Anwer F; Schatz JH; Mahadevan D; Persky DO
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):58-64. PubMed ID: 29056470
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]